Identification of recent cannabis use: Whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration

Clinical Chemistry

Volumn 57, Issue 10, 2011, Pages 1406-1414

  Schwope, David M ^a   Karschner, Erin L ^a   Gorelick, David A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOL; CANNABIS; DELTA9(11) TETRAHYDROCANNABINOL; GLUCURONIDE; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOLIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANNABIS SMOKING; CIGARETTE SMOKING; CLINICAL ARTICLE; DRUG GLUCURONIDATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; CANNABIDIOL; CANNABINOIDS; CANNABINOL; CANNABIS; FEMALE; GLUCURONIDES; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL; YOUNG ADULT;

CANNABIS;

EID: 80053429079     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.171777     Document Type: Article

References (37)

1. Compton R, Berning A. Results of the 2007 national roadside survey of alcohol and drug use by drivers. DOT HS 811 175. Washington (DC): NHTSA; 2009.
2. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of Delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 2007;31:288-93. (Pubitemid 46911627)
3. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992;16:276-82.
4. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J, et al. Detection of marijuana use by oral fluid and urine analysis following singledose administration of smoked and oral marijuana. J Anal Toxicol 2001;25:289-303. (Pubitemid 32656280)
5. Matsunaga T, Iwawaki Y, Watanabe K, Yamamoto I, Kageyama T, Yoshimura H. Metabolism of delta-9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 1995;56:2089-95.
6. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007;80:1415-9. (Pubitemid 46367067)
7. Halldin MM, Carlsson S, Kanter SL, Widman M, Agurell S. Urinary metabolites of delta-1-tetrahydrocannabinol in man. Arzneim Forsch 1982;32:764-8.
8. Williams PL, Moffat AC. Identification in human urine of Delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 1980;32:445-8. (Pubitemid 11251991)
9. Wall ME, Sadler BM, Brine D, Taylor H, Perez- Reyes M. Metabolism, disposition, and kinetics of Delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-63. (Pubitemid 13006304)
10. Mareck U, Haenelt N, Geyer H, Guddat S, Kamber M, Brenneisen R, et al. Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Anal 2009;1:505-10.
11. Skopp G, Pötsch L, Ganßmann B, Mauden M, Richter B, Aderjan R, Mattern R. Freie und glucuronidierte Cannabinoide im Urin-Untersuchungen zur Einschätzung des Konsumverhaltens. Rechtsmedizin 1999;10:21-8. (Pubitemid 30095427)
12. Law B, Mason PA, Moffat AC, Gleadle RI, King LJ. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 1984;36:289-94. (Pubitemid 14101357)
13. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992;16:228-35.
14. Skopp G, Potsch L. Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking. J Anal Toxicol 2008;32:160-4. (Pubitemid 351362750)
15. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, et al. Delta9- tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009;55:2180-9.
16. Schwope DM, Scheidweiler KB, Huestis MA. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011;401:1273-83.
17. McCurdy HH, Callahan LS, Williams RD. Studies on the stability and detection of cocaine, benzoylecgonine, and 11-nor-Delta-9-tetrahydrocannabinol- 9-carboxylic acid in whole blood using Abuscreen radioimmunoassay. J Forensic Sci 1989;34:858-70. (Pubitemid 19186955)
18. Christophersen AS. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 1986;10:129-31. (Pubitemid 17100544)
19. Stout PR, Horn CK, Lesser DR. Loss of THCCOOH from urine specimens stored in polypropylene and polyethylene containers at different temperatures. J Anal Toxicol 2000;24:567-71.
20. Skopp G, Potsch L. Stability of 11-nor-Delta(9)-carboxy- tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin Chem 2002;48:301-6. (Pubitemid 34107267)
21. Wong AS, Orbanosky MW, Reeve VC, Beede JD. Stability of delta-9-tetrahydrocannabinol in stored blood and serum. In: Hawks RL, ed. The analysis of cannabinoids in biological fluids. Rockville (MD): National Institute on Drug Abuse; 1982. p 119-24. (Pubitemid 13127564)
22. Schwilke EW, Karschner EL, Lowe RH, Gordon AM, Cadet JL, Herning R, Huestis MA. Intra-and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. Clin Chem 2009;55:1188-95.
23. Manno JE, Manno BR, Kemp PM, Alford DD, Abukhalaf IK, McWilliams ME, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of Delta-9-tetrahydrocannabinol, 11-hydroxy-Delta-9- tetrahydrocannabinol, and 11-nor-Delta-9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 2001;25:538-49. (Pubitemid 32939055)
24. Hunault CC, Mensinga TT, De Vries I, Kelholt-Dijkman HH, Hoek J, Kruidenier M, et al. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl) 2008;201:171-81.
25. Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, Cook CE. Comparison of effects of marijuana cigarettes of three different potencies. Clin Pharmacol Ther 1982;31:617-24. (Pubitemid 13105521)
26. Perez-Reyes M, Owens SM, Di Guiseppi S. The clinical pharmacology and dynamics of marijuana cigarette smoking. J Clin Pharmacol 1981;21:201S-7S.
27. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 2006;85:114-22. (Pubitemid 44468137)
28. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Clinical effects and plasma levels of Delta9-tetrahydrocannabinol (Delta9-THC) in heavy and light users of cannabis. Psychopharmacology 1981;74:208-12. (Pubitemid 11034573)
29. Wall ME, Taylor HL. Conjugation of acidic metabolites of Delta-8 and Delta-9-THC in man. In: Harvey DJ, ed. Marihuana '84: proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press; 1985. p 69-76.
30. Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA. Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9- tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 2007;31:477-85. (Pubitemid 350164290)
31. Hemphill JK, Turner JC, Mahlberg PG. Cannabinoid content of individual plant organs from different geographical strains of Cannabis sativa L. J Nat Prod 1980;43:112-22. (Pubitemid 11236028)
32. ElSohly MA. Chem constituents of cannabis. In: Grotenhermen F, Russo E, eds. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York: Haworth Integrative Healing Press; 2002. p 27-36.
33. Pomahacova B, van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol 2009;21:1108-12.
34. ElSohly HN, ElSohly MA. Marijuana smoke condensate: chemistry and pharmacology. In: El- Sohly, ed. Marijuana and the cannabinoids. Totowa (NJ): Humana Press; 2007. p 67-96.
35. Moran J, Radomińska-Pandya A, Miller G, Finel M, Gallus-Zawada A, Bratton S, et al. Characterization of human hepatic and extrahepatic UDPglucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 2009;37:1496-504.
36. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral Delta9- tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 2011;57:66-75.
37. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Delta-9- tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992;16:283-90.